
Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced the initiation of a double-blinded placebo controlled Phase 2 study of PRX302 (study name: TRIUMPH) in patients with benign prostatic hyperplasia (BPH), a painful and bothersome urological condition that affects more than 50 million men worldwide. The trial will evaluate the efficacy of PRX302 versus placebo using the optimal treatment volume established in the open-label Phase 2 study results announced in November, 2008.
“Results from our open-label Phase 2 study demonstrated that PRX302 has the potential to establish a new standard of care for the treatment of BPH,” said Dr. Fahar Merchant, President and Chief Executive Officer of Protox. “With results from TRIUMPH expected in the second half of 2009, we are confident this study will validate the value of PRX302 to our potential partners, and most importantly, patients suffering from BPH.”